Episode description
Discover the hurdles and breakthroughs in glycoengineering, including the high costs of activated sugars.
Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, unveils eversyn's multi-step biocatalysis process, designed to significantly drive down costs and make in vitro glycoengineering more accessible on a large scale.
Key Insights:
- Uncover the power of multistep biocatalysis in driving down costs and making in vitro glycoengineering more accessible.
- Bridge the Gap between academia and industry in glycoengineering and thus ensure a smoother integration of groundbreaking glycoengineering technologies into the industrial landscape.
- Gain valuable insights into the challenges and triumphs of transitioning from pure science to entrepreneurship, offering aspiring scientists a roadmap to navigate the unknown.
Connect with Thomas Rexer:
LinkedIn: https://www.linkedin.com/in/thomas-rexer
Website: www.eversyn.de
Next Step:
Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com